MAIA Biotechnology, Inc.
New York Stock Exchange ArcaCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Vlad Vitoc
- Full Time Employees
- 13
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 444 West Lake Street Chicago IL United States of America 60606
- IPO Date
- Jul 28, 2022
- CIK
- 0001878313
- Website
- maiabiotech.com
- Similar Companies
- Business
- MAIA Biotechnology, Inc. (MAIA) develops and commercializes targeted immunotherapies for cancer, focusing on first-in-class drugs with novel mechanisms of action aimed at telomerase-positive cancer cells, particularly in non-small cell lung cancer (NSCLC). The company offers ateganosine (THIO or 6-thio-2'-deoxyguanosine), its lead investigational asset, a dual-mechanism telomere targeting agent that induces immunogenic cell death and enhances immunotherapy efficacy; THIO targets advanced NSCLC patients, often in combination with immune checkpoint inhibitors like cemiplimab (Libtayo); its pipeline advances through Phase 2 (THIO-101) and Phase 3 (THIO-104) trials for ICI-resistant NSCLC. MAIA Biotechnology operates in the oncology biotechnology sector, serving patients with advanced cancers through clinical-stage programs; it maintains headquarters in Chicago, Illinois, at 444 West Lake Street, Suite 1700; the company was founded in 2018. Recent developments include a $2.25 million private placement in September 2025 and a $736,600 private placement in October 2025 to fund clinical advancement; a $2.3 million grant award from the National Institutes of Health in September 2025 for the THIO-101 Phase 2 trial; positive Phase 2 THIO-101 data presented in 2025 showing 38% response rates, 17.8 months overall survival, and 30-month patient survival; trial updates at SITC 2025, IASLC World Conference, and AACR-NCI-EORTC; open market share purchases by CEO Vlad Vitoc and directors in November 2025 signaling confidence; and plans to initiate a digital asset treasury strategy in October 2025 focused on top-tier crypto assets.
Company News
MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
MAIA: Meta Taps MongoDB CEO to Lead New Enterprise AI Platform, ft. Seth Fiegerman | Open Interest
MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO
MAIA: Tiffany Wilding Says Labor Costs Are Easing, Supporting Fed Patience, ft. Tiffany Wilding
MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
MAIA: High Bar For ECB Surprise, Alphabet CAPEX In Focus: 3 Minutes MLIV
MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial
MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial
MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer
MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University
MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial
MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial
MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion